Manila Times Business
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 - WALTHAM, Mass. and BOULDER, Colo., June 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced preclinical data from its novel, potential be
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Genesis Wins Best Fixed Income Trading Solution
1h ago
Veyond Metaverse Closes Strategic Investment from Japan-Based Private Investor as Global Commercial Momentum Accelerates Across Its XR Medical Telepresence Platform
1h ago
EXL and Databricks expand collaboration to help enterprises build trusted data foundations for AI
1h ago
BlockchAIn Announces Preliminary Inclusion in Russell Microcap® Index
1h ago